An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
The goal of this clinical trial is to evaluate the long-term safety and tolerability of
zagociguat in patients with MELAS who completed study medication treatment in the lead-in
study TIS6463-203. TIS6463-204 is evaluating zagociguat in an open-label extension study
...
Age: Birth - 66+
Gender: All
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
The study is conducted in New York, New York at The Cohen Center for Recovery from
Complex Chronic Illness at Mount Sinai.
This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled
clinical trial of sirolimus (also known as rapamycin) in adu...
Age: 18 years - 66+
Gender: All
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
This will be a pilot multi-arm clinical trial investigating the feasibility of 6 weeks of Lumbrokinase (LK) as an intervention in three clinical cohorts:
Long Covid (LC)
Post-treatment Lyme disease syndrome (PTLDS)
Myalgic encephalomyelitis/chronic fatigue syndrome (ME...
Age: 18 years - 66+
Gender: All
Immunologic Basis of Food Protein-Induced Enterocolitis Syndrome
This is a phase I multicenter clinical trial that aims to find the optimal dose for
conducting a novel low-dose, multi-day oral food challenge (OFC) protocol for diagnosing
food protein-induced enterocolitis syndrome (FPIES). Individuals ages 1-60 years with a
histor...
Age: 1 year - 60 years
Gender: All
Immunologic Basis of Food Protein-Induced Enterocolitis Syndrome
This is a phase I multicenter clinical trial that aims to find the optimal dose for
conducting a novel low-dose, multi-day oral food challenge (OFC) protocol for diagnosing
food protein-induced enterocolitis syndrome (FPIES). Individuals ages 1-60 years with a
histor...
Age: 1 year - 60 years
Gender: All
A Phase 2 Basket Study of Vosoritide in Children With Turner Syndrome, SHOX Deficiency and Noonan Syndrome With an Inadequate Response to Human Growth Hormone
The purpose of this basket study in children with Turner syndrome, SHOX deficiency, and
Noonan syndrome is to evaluate the effect of 3 doses of vosoritide versus hGH on growth
as measured by AGV after 6 months of treatment. The long-term efficacy and safety of
vosori...
Age: 3 - 11 years
Gender: All
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus
Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in
Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell
Transplantation
Age: 18 years - 66+
Gender: All
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells).
The purpose of this study is to assess the safety of venetoclax in combination with
obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in
disease act...
Age: 18 years - 66+
Gender: All
RECOVER-SLEEP: Platform Protocol
The platform protocol is designed to be flexible so that it is suitable for a range of
study settings and intervention types. Therefore, the platform protocol provides a
general protocol structure that can be shared by multiple interventions and allows
comparative an...
Age: 18 years - 66+
Gender: All
RECOVER-SLEEP: Platform Protocol
The platform protocol is designed to be flexible so that it is suitable for a range of
study settings and intervention types. Therefore, the platform protocol provides a
general protocol structure that can be shared by multiple interventions and allows
comparative an...
Age: 18 years - 66+
Gender: All
A Phase 2b Study of Zagociguat in Patients with MELAS
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period,
crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs.
placebo when administered daily for 12 weeks in participants with genetically and
phenotypi...
Age: 18 - 75 years
Gender: All
A Phase 2b Study of Zagociguat in Patients With MELAS
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period,
crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs.
placebo when administered daily for 12 weeks in participants with genetically and
phenotypi...
Age: 18 - 75 years
Gender: All
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
This study is researching an experimental drug called linvoseltamab combined with another
drug called dupilumab. The study is looking at patients who have severe IgE-mediated food
allergy. If the patient has an allergy, the body's defense system (immune system)
overr...
Age: 18 - 50 years
Gender: All
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and
expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid
leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysp...
Age: 18 years - 66+
Gender: All
MCG Discovery Study in Emergency Departments
This prospective discovery study is designed to demonstrate the feasibility of using an
unshielded, mobile MCG device in an Emergency Department (ED) setting. The main question
it aims to answer is whether interpretable data can be reliably collected as part of an
ED...
Age: 18 years - 66+
Gender: All
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when
administered at the maximum approved dose in low-risk Myelodysplastic Syndrome
participants who require red blood cell transfusions.
Age: 18 years - 66+
Gender: All
Persuasive Health Communication Intervention for HIV/HCV
A major impediment to emergency department (ED)-based HIV/HCV screening success is that
often ED patients at risk for, or later diagnosed with, HIV and HCV decline testing. In
this R01 project, the research team will assess how well a promising, easy-to-use,
one-time...
Age: 18 years - 66+
Gender: All
Persuasive Health Communication Intervention for HIV/HCV
A major impediment to emergency department (ED)-based HIV/HCV screening success is that
often ED patients at risk for, or later diagnosed with, HIV and HCV decline testing. In
this R01 project, the research team will assess how well a promising, easy-to-use,
one-time...
Age: 18 years - 66+
Gender: All
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel)
work together in treating patients with Richter's syndrome. Richter's syndrome occurs
when chronic lymphocytic leukemia and/or small lymphocytic leukemia transforms into an
aggres...
Age: 18 years - 66+
Gender: All
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel)
work together in treating patients with Richter's syndrome. Richter's syndrome occurs
when chronic lymphocytic leukemia and/or small lymphocytic leukemia transforms into an
aggres...
Age: 18 years - 66+
Gender: All